Chris O’Dell, SVP of market solutions at Turquoise Health, explains why the administration’s efforts aren’t likely to impact generics in the near future.
Chris O'Dell
Advertisement
Articles by Chris O'Dell
Chris O’Dell, SVP of market solutions at Turquoise Health, discusses the impact on the various middle-men involved in drug-pricing.
Chris O’Dell, SVP of market solutions at Turquoise Health, discusses why it's important to a shine a light on this aspect of the healthcare ecosystem.
Chris O’Dell, SVP of market solutions at Turquoise Health, explains the timeline to expect changes to prescription drug prices based on current DTC trend.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Stock Becomes UK’s Biggest Stock
2
Basel, Switzerland, Puts Out Call for Pharma Execs
3
Pfizer’s Proven Playbook: Buy, Partner, Scale, Spin-Off, Optimize
4
HHS and FDA Appoint Richard Pazdur as Director of The Center for Drug Evaluation and Research
5
